# Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

> **NCT03455777** · PHASE2 · WITHDRAWN · sponsor: **Akcea Therapeutics**

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** AKCEA-ANGPTL3-LRX

## Key facts

- **NCT ID:** NCT03455777
- **Lead sponsor:** Akcea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-12
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to lack of available patients meeting entry criteria
- **Last updated:** 2018-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455777, "Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03455777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*